Lewes, DE -- (SBWIRE) -- 08/22/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Cree, Inc. (NASDAQ:CREE), Amgen, Inc. (NASDAQ:AMGN), Diamond Foods, Inc. (NASDAQ:DMND), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Cree, Inc. (NASDAQ:CREE) increased +0.07% and closed at $56.71 on a traded volume of 2.3 million shares, in comparison to 2.61 million shares of average trading volume. So far this year, the stock is up over 66.89%.
The company has a total market capitalization of $6.68Billion and its total outstanding shares are 117.87 million. Cree, Inc. (Cree) develops and manufactures semiconductor materials and devices primarily based on silicon carbide (SiC), gallium nitride (GaN) and related compounds. It focuses its expertise in SiC and GaN on light emitting diode (LED) products.
What was the Moving Force behind CREE On Bullish Run? Read This Research Report on CREE
Amgen, Inc. (NASDAQ:AMGN) plunged -0.90% and closed at $104.65 on a traded volume of 2.35 million shares, whereas its average trading volume is 3.10 million shares. In the last three months, the stock is up +0.39%. The Intra-day range for the stock is $103.88 and $106.18. Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses.
Has AMGN Found The Bottom And Ready To Gain Momentum? Find Out Here
Diamond Foods, Inc. (NASDAQ:DMND) jumped up 19.13% and closed at $22.79. So far in three months, the stock is up 33.35%. The 52-week range for the stock is $12.85 and $23.38 and during the previous trading session the stock touched its highest price at $23.38. Its introductory price for the day was $22.10, with the overall traded volume of 2.31million shares. Diamond Foods, Inc. (Diamond) is a packaged food company focused on building, acquiring and energizing brands. Diamond specializes in processing, marketing and distributing snack products and culinary, in-shell and ingredient nuts.
For How Long DMND Gloss will Attract Investors? Find out via this report
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after opening its shares at the price of $19.87, jumped up 1.61% to close at $20.18 for the day. The stock moved on a traded volume of 2.23 million shares, in comparison to 2.23 million shares of average trading volume.
The 52-week range for the stock is $1.71and $21.85 and during the previous trading session the stock touched its highest price at $20.74. Its introductory price for the day was $19.87. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis.
Will ACAD Continue To Move Higher? Find Out Here
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/